Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment
Authors
Keywords
-
Journal
JAMA Network Open
Volume 5, Issue 4, Pages e228392
Publisher
American Medical Association (AMA)
Online
2022-04-21
DOI
10.1001/jamanetworkopen.2022.8392
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The PrecivityAD™ Test: Accurate and Reliable LC-MS/MS Assays for Quantifying Plasma Amyloid Beta 40 and 42 and Apolipoprotein E Proteotype for the Assessment of Brain Amyloidosis
- (2021) Kristopher M. Kirmess et al. CLINICA CHIMICA ACTA
- A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
- (2021) Tim West et al. Molecular Neurodegeneration
- Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
- (2021) Shorena Janelidze et al. JAMA Neurology
- Expected wait times for access to a disease‐modifying Alzheimer's treatment in the United States
- (2021) Soeren Mattke et al. Alzheimers & Dementia
- Early Clinical Utility Data of a Blood Biomarker Test in the Evaluation of Mild Cognitive Impairment
- (2021) Mark Monane et al. Innovation in Aging
- Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease
- (2020) Sanka Amadoru et al. Alzheimers Research & Therapy
- Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment
- (2020) Philip S. Insel et al. JAMA Neurology
- Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation
- (2020) Michelle E. Farrell et al. NEUROLOGY
- Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology
- (2019) Vincent Doré et al. Alzheimers & Dementia
- Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia
- (2019) Gil D. Rabinovici et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
- (2019) Suzanne E. Schindler et al. NEUROLOGY
- Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
- (2019) Justin M. Long et al. CELL
- Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale
- (2018) Michael Navitsky et al. Alzheimers & Dementia
- High performance plasma amyloid-β biomarkers for Alzheimer’s disease
- (2018) Akinori Nakamura et al. NATURE
- Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology
- (2018) Renaud La Joie et al. Alzheimers & Dementia
- Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation
- (2015) Sylvia Villeneuve et al. BRAIN
- Three dimensions of the amyloid hypothesis: time, space and 'wingmen'
- (2015) Erik S Musiek et al. NATURE NEUROSCIENCE
- Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010
- (2012) Thomas G. Beach et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
- (2012) Christopher M Clark et al. LANCET NEUROLOGY
- The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
- (2011) Eric Karran et al. NATURE REVIEWS DRUG DISCOVERY
- Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: Determining sample size for treatment trials
- (2011) Jennifer L. Whitwell et al. PARKINSONISM & RELATED DISORDERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now